LIPELLA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.725 USD | +1.97% |
|
+0.69% | -28.92% |
| Apr. 17 | Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board | CI |
| Apr. 09 | Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 5.92 | 5.104 | - | - |
| Enterprise Value (EV) 1 | 5.92 | 5.104 | 5.104 | 5.104 |
| P/E ratio | -1.32 x | -2.69 x | -3.15 x | -2.9 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -1.5 x | -1 x | -0.67 x |
| FCF Yield | - | -66.6% | -99.9% | -150% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 5,804 | 7,040 | - | - |
| Reference price 2 | 1.020 | 0.7250 | 0.7250 | 0.7250 |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -3.4 | -5.1 | -7.65 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.4 | -5.1 | -7.65 |
| Net income 1 | -4.619 | -3.4 | -5.1 | -7.65 |
| Net margin | - | - | - | - |
| EPS 2 | -0.7700 | -0.2700 | -0.2300 | -0.2500 |
| Free Cash Flow 1 | - | -3.4 | -5.1 | -7.65 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -3.4 | -5.1 | -7.65 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.725
USD
Average target price
2
USD
Spread / Average Target
+175.86%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.92% | 5.1M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.98% | 22.18B | |
| -16.67% | 21.2B | |
| -9.86% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- LIPO Stock
- Financials Lipella Pharmaceuticals Inc.
